Kaempferol-3-rutinoside
(Synonyms: 莰菲醇-3-O-芸香糖苷) 目录号 : GN10672
Kaempferol-3-rutinoside是一种存在于多种植物中的黄酮类糖苷，又称为Nicotiflorin，具有降血脂、抗糖化和神经保护作用。
Cas No.:17650-84-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Kaempferol-3-rutinoside is a flavonoid glycoside that exists in a variety of plants and is also known as Nicotiflorin[1]. Kaempferol-3-rutinoside has lipid-lowering, anti-glycation, and neuroprotective effects[2-3]. Kaempferol-3-rutinoside can protect cells from oxidative stress-induced damage by increasing the activity of antioxidant enzymes such as superoxide dismutase and catalase[4].
In vitro, After 4 hours of hypoxia and 12 hours of reoxygenation, the endothelial nitric oxide synthase (eNOS) activity, mRNA and protein levels in Kaempferol-3-rutinoside (25, 50, 100μg/ml) treated primary rat brain microvascular endothelial cells were significantly increased compared with untreated hypoxic reoxygenated cells and normally cultured cells[5]. Kaempferol-3-rutinoside (0, 25, 50, 75, 100μg/ml) treatment of human renal epithelial cells (HK-2) significantly reduced hypoxia/reoxygenation-induced cell apoptosis, as evidenced by decreased expression of pro-apoptotic proteins caspase 3 and Bad, and increased expression of anti-apoptotic protein Bcl-2. Moreover, in HK-2 cells treated with Kaempferol-3-rutinoside (75μg/ml) under hypoxia/reoxygenation conditions, cell apoptosis was further inhibited by activating transcription factor 3 (ATF3)[6].
In vivo, Kaempferol-3-rutinoside (2.5, 5, and 10mg/kg) was administered via tail vein injection to treat a male Sprague-Dawley (SD) rat model of permanent focal cerebral ischemia, with administration immediately following ischemia onset. Kaempferol-3-rutinoside significantly reduced the volume of ischemic brain damage in a dose-dependent manner at all three doses and improved behavioral deficits caused by permanent middle cerebral artery occlusion (pMCAO)[7]. Kaempferol-3-rutinoside (10mg/kg) was administered via tail vein injection to treat a male Sprague-Dawley rat model of transient middle cerebral artery occlusion/reperfusion (MCAO/R)-induced cerebral ischemia-reperfusion injury, with administration at the start of reperfusion. Kaempferol-3-rutinoside treatment significantly reduced the volume of ischemic brain damage, decreased the number of apoptotic cells, downregulated the expression of p-JAK2, p-STAT3, caspase-3, and Bax, reduced the immunoreactivity of Bax, and increased the expression and immunoreactivity of Bcl-2 protein[8].
References:
[1] Patel DK. Medicinal Importance, Pharmacological Activities and Analytical Aspects of a Flavonoid Glycoside 'Nicotiflorin' in the Medicine. Drug Metab Bioanal Lett. 2022;15(1):2-11.
[2] Huang JL, Fu ST, Jiang YY, et al. Protective effects of Nicotiflorin on reducing memory dysfunction, energy metabolism failure and oxidative stress in multi-infarct dementia model rats. Pharmacol Biochem Behav. 2007 Apr;86(4):741-8.
[3] Papaioannou P, Lazari D, Karioti A, et al. Phenolic compounds with antioxidant activity from Anthemis tinctoria L. (Asteraceae). Z Naturforsch C J Biosci. 2007 May-Jun;62(5-6):326-30.
[4] Yang C, Li F, Zhang X, et al. Phenolic antioxidants from Rosa soulieana flowers. Nat Prod Res. 2013;27(21):2055-8.
[5] Li R, Guo M, Zhang G, et al. Nicotiflorin reduces cerebral ischemic damage and upregulates endothelial nitric oxide synthase in primarily cultured rat cerebral blood vessel endothelial cells. J Ethnopharmacol. 2006 Aug 11;107(1):143-50.
[6] Wang L, Li C, Guan C, et al. Nicotiflorin attenuates cell apoptosis in renal ischemia-reperfusion injury through activating transcription factor 3. Nephrology (Carlton). 2021 Apr;26(4):358-368.
[7] Li R, Guo M, Zhang G, et al. Neuroprotection of nicotiflorin in permanent focal cerebral ischemia and in neuronal cultures. Biol Pharm Bull. 2006 Sep;29(9):1868-72.
[8] Hu GQ, Du X, Li YJ, et al. Inhibition of cerebral ischemia/reperfusion injury-induced apoptosis: nicotiflorin and JAK2/STAT3 pathway.
Kaempferol-3-rutinoside是一种存在于多种植物中的黄酮类糖苷，又称为Nicotiflorin[1]，具有降血脂、抗糖化和神经保护作用[2-3]。Kaempferol-3-rutinoside可以通过增加超氧化物歧化酶和过氧化氢酶等抗氧化酶的活性，保护细胞免受氧化应激诱导的损伤[4]。
在体外，经4小时缺氧和12小时复氧处理后，与未处理的缺氧复氧细胞及正常培养的细胞相比，Kaempferol-3-rutinoside（25、50、100μg/ml）处理的原代大鼠脑微血管内皮细胞中内皮型一氧化氮合酶（eNOS）活性、mRNA和蛋白水平显著提高[5]。Kaempferol-3-rutinoside（0、25、50、75、100μg/ml）处理人肾上皮细胞（HK-2），显著降低了缺氧/复氧诱导的细胞凋亡，表现为降低促凋亡蛋白caspase3和Bad的表达，增加抗凋亡蛋白Bcl-2的表达。此外，Kaempferol-3-rutinoside（75μg/ml）处理的HK-2细胞在缺氧/复氧条件下，通过激活转录因子3（ATF3），进一步抑制了细胞凋亡[6]。
在体内，Kaempferol-3-rutinoside（2.5、5和10mg/kg）通过尾静脉注射给药，用于治疗永久性局灶性脑缺血的雄性Sprague-Dawley（SD）大鼠模型，给药时间为缺血发生后立即进行。Kaempferol-3-rutinoside在所有三个剂量下均能以剂量依赖性方式显著减少缺血性脑损伤的体积，并改善由永久性大脑中动脉闭塞（pMCAO）引起的行为缺陷[7]。Kaempferol-3-rutinoside（10mg/kg）通过尾静脉注射给药，用于治疗短暂性大脑中动脉闭塞/再灌注（MCAO/R）诱导的脑缺血再灌注损伤的雄性Sprague-Dawley大鼠模型，给药时间为再灌注开始时。Kaempferol-3-rutinoside处理显著减少了缺血性脑损伤的体积，降低了细胞凋亡的数量，下调了p-JAK2、p-STAT3、caspase-3和Bax的表达，减少了Bax的免疫反应性，并增加了Bcl-2蛋白的表达和免疫反应性[8]。
| Cell experiment [1]: | |
Cell lines | Human kidney epithelial cells (HK-2) |
Preparation Method | HK-2 cells were inoculated into 24-well plates at a density of 1×10⁴ cells per well and cultured until they reached the logarithmic phase of growth. The cells were then subjected to hypoxia (95%N₂, 5%CO₂) for 24 hours and subsequently reoxygenated (95%air, 5%CO₂) for 6 hours to establish the hypoxia-reoxygenation (H-R) model. The cells were divided into three groups: control group (cultured under normal conditions), H-R group, and Kaempferol-3-rutinoside plus H-R group. |
Reaction Conditions | 25, 50, 75, 100μg/mL Kaempferol-3-rutinoside; 24 hours of hypoxia followed by 6 hours of reoxygenation |
Applications | Kaempferol-3-rutinoside significantly reduced cell apoptosis by decreasing the expression of pro-apoptotic proteins caspase-3 and Bad, and increasing the expression of anti-apoptotic protein Bcl-2. |
| Animal experiment [2]: | |
Animal models | Sprague-Dawley rats |
Preparation Method | Transient middle cerebral artery occlusion (MCAO) was performed on the right side using a nylon filament. After 2 hours of ischemia, the fiber was gently removed to enable reperfusion of the middle cerebral artery. Kaempferol-3-rutinoside (10.0mg/kg) was administered by tail vein injection to the Kaempferol-3-rutinoside group at the beginning of reperfusion. Vehicle was administered to the I/R and sham groups in the same manner. After 24 hours of reperfusion, rats were executed. |
Dosage form | 10.0mg/kg; i.v. |
Applications | Kaempferol-3-rutinoside altered the shape and structure of injured neurons, decreased the number of apoptotic cells, down-regulates expression of p-JAK2, p-STAT3, caspase-3, and Bax, decreased Bax immunoredactivity, and increased Bcl-2 protein expression and immunoreactivity. |
References: | |
| Cas No. | 17650-84-9 | SDF | |
| 别名 | 莰菲醇-3-O-芸香糖苷 | ||
| 化学名 | 5,7-dihydroxy-2-(4-hydroxyphenyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one | ||
| Canonical SMILES | CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC=C(C=C5)O)O)O)O)O)O)O | ||
| 分子式 | C27H30O15 | 分子量 | 594.52 |
| 溶解度 | ≥ 59.5mg/mL in DMSO | 储存条件 | Store at 2-8°C,protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.682 mL | 8.4101 mL | 16.8203 mL |
| 5 mM | 0.3364 mL | 1.682 mL | 3.3641 mL |
| 10 mM | 0.1682 mL | 0.841 mL | 1.682 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet